Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.
CFD's zijn complexe instrumenten en houden vanwege de hefboomwerking een hoog risico in op grote verliezen. 70% van de particuliere beleggers verliest geld bij de handel in CFD's met deze aanbieder.U moet nagaan of u wel degelijk begrijpt hoe CFD's werken en of u zich het hoge risico op geldverlies kunt veroorloven. Raadpleeg onze risicoverklaring
Beoordelingen en recensies
Beoordelingen en recensies
